New research challenges concerns that tirzepatide harms the eyes, finding lower rates of diabetic retinopathy instead.

Samsung and Mass General are studying whether Galaxy Watch8 can support adults starting GLP-1RA therapy by tracking activity, ...

MADISON, Conn. (WTNH) — A center in Madison is focusing on personalized treatments designed to help people feel their best from the inside out. LIVation offers a range of wellness services including ...

Please provide your email address to receive an email when new articles are posted on . Adults who switched from 10 mg or 15 mg tirzepatide to 5 mg maintained 67.9% of their weight loss. Both ...

Side effects like nausea, vomiting, diarrhea and constipation are common soon after starting GLP-1s or increasing the drug’s dosage. A nutrient-dense diet and regular exercise are essential when on a ...

Testosterone levels in men tend to drop naturally with age. And research has linked low testosterone levels with excess weight particularly around the abdominal area. With this in mind, it seems ...

The best low-impact exercises for polymyalgia rheumatica (PMR) include walking, swimming, resistance training, and stretching to maintain mobility and strength.

With this in mind, it seems natural that using testosterone replacement therapy (TRT) for weight loss purposes could be a potential solution. But while it’s been marketed for this, experts caution ...

Three major reviews commissioned by the World Health Organization find that GLP-1 drugs including tirzepatide (sold as Mounjaro and Zepbound), semaglutide (Ozempic and Wegovy), and liraglutide ...

Reduced muscle mass, aka sarcopenia, is a common side effect of weight loss induced by GLP-1 receptor agonists, such as Ozempic, Wegovy, and Zepbound. However, muscle loss often results from rapid ...

As a dietitian, I’m often asked about new and emerging methods for weight management. One that’s been gaining attention recently is red light therapy, which is a treatment often associated with skin ...

A new therapy for genetic hearing loss has just been approved by the Food and Drug Administration (FDA). The treatment, Otarmeni (lunsotogene parvec-cwha), is the first-ever dual adeno-associated ...